From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone

  title={From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone},
  author={Charles B. Nemeroff and Jeffrey A. Lieberman and Peter J. Weiden and Philip D. Harvey and John W. Newcomer and Alan F. Schatzberg and Clinton D. Kilts and David G. Daniel},
  journal={CNS Spectrums},
  pages={1 - 20}
ABSTRACT Ziprasidone is a second-generation antipsychotic that received Food and Drug Administration approval in February 2001. It has a unique receptor profile that includes high-affinity antagonist activity at dopamine D2 receptors, inverse agonist activity at serotonin (5-HT)2A receptors, agonist activity at 5-HT1A receptors, and a relatively high affinity for the serotonin and norepinephrine transporters. The 5-HT1A affinity, together with the inhibitory effect on monoamine reuptake, may… 

Ziprasidone in bipolar disorder

  • M. Versiani
  • Psychology, Medicine
    Expert opinion on pharmacotherapy
  • 2006
Open-label treatment for up to 52 weeks supported the sustained efficacy of ziprasidone in bipolar disorder, and the drug was very well tolerated by patients with bipolar disorder and did not cause increased weight, glucose or lipid levels.

Ziprasidone in the Treatment of Affective Disorders: A Review

Ziprasidone appears to offer some antidepressant effect in patients with major depressive episode and resistant to treatment, as demonstrated in add‐on open‐label studies with ziprasid one plus selective serotonin reuptake inhibitor (SSRI).

Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review

Emerging evidence indicates that in patients with bipolar disorder, ziprasidone provides valid efficacy and remarkable safety when administered alone for the treatment of manic and mixed episodes and when ziprasIDone is administered in combination with lithium or valproate for the prevention of affective relapses and recurrences.

High-dose ziprasidone in treatment-resistant schizophrenia and affective spectrum disorders: a case series.

A retrospective electronic record review of 106 evaluable records of patients with schizophrenia and affective spectrum disorders treated with higher doses of ziprasidone in inpatient, partial hospital, and outpatient settings at a community general hospital in the southwest suburbs of Cleveland, OH found large improvement in symptom severity and effects on the QTc interval were found.

Ziprasidone in the treatment of mania in bipolar disorder

Data suggest that ziprasidone may be a first line treatment for patients with bipolar mania, but this is a relatively new medication for which adverse events after long-term use and/or in vulnerable patient populations must be studied.

Long-Term Improvement in Efficacy and Safety After Switching to Ziprasidone in Stable Outpatients with Schizophrenia

Ziprasidone was well tolerated, and patients demonstrated significant improvement in metabolic parameters and in all movement disorder assessments, as well as in intent-to-treat population.

Treatment of bipolar disorder: the evolving role of atypical antipsychotics.

  • R. Perlis
  • Psychology, Medicine
    The American journal of managed care
  • 2007
Although head-to-head comparisons are scarce, meta-analysis data suggest that olanzapine, risperidone, quetiAPine, ziprasid one, and aripiprazole have similar antimanic efficacy; therefore, AAP selection for this indication should be guided by other considerations such as safety, tolerability, and cost.

Safety of the electroconvulsive therapy-ziprasidone combination.

8 female inpatients who underwent ECT while receiving ziprasidone (20-80 mg/d) as part of their regimen were well tolerated and the combination was well tolerated with only minimal adverse effects and unremarkable changes in corrected QT interval.

A Comparison of Ziprasidone and Risperidone in the Long-Term Treatment of Schizophrenia: A 44-Week, Double-Blind, Continuation Study

Ziprasidone was associated with a more favourable effect on extrapyramidal symptom (EPS) measures and prolactin as well as less weight gain than risperidone aswell as fewer adverse effects on weight, EPS measures, and Prolactin than ris peridone.



Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials.

  • J. Kane
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 2003
Atypical antipsychotic ziprasidone has been shown in placebo- and active-comparator-controlled clinical studies to be effective in treating the positive, negative, and affective symptoms of schizophrenia.

Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder.

A possible augmentation role for ziprasidone when used in conjunction with SSRIs in SSRI-resistant MDD is suggested, with no clinically significant QTc prolongation or severe adverse events observed in any of the study participants.

The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.

Ziprasidone targets the key hypothetical neurochemical disturbance in psychosis-excessive dopamine neurotransmission at dopamine D2 receptors in the mesolimbic pathway of the brain-presumably responsible for the positive symptoms of schizophrenia.

Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.

It is confirmed that atypicals are associated with improvement of an expanded spectrum of symptoms in treatment-resistant patients as well as traditional antipsychotic treatment with all 3 atypical medications.

Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.

It is suggested that outpatients who partially respond to conventional antipsychotics, risperidone, or olanzapine may experience improved control of psychotic symptoms following a switch to ziprasidone.

Olanzapine: an updated review of its use in the management of schizophrenia.

Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in thetreatment of some patients with first-episode or treatment-resistant schizophrenia.

A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.

It is affirm that ziprasidone is similar to other novel antipsychotics in having greater 5-HT(2) than D( 2) receptor occupancy at therapeutic doses and suggest that the optimal effective dose of ziprasIDone is closer to 120 mg/day than to the lower doses suggested by previous PET studies.

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.